A Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis: A Single-Arm Clinical Trial of Feasibility

被引:3
|
作者
Petoe, Matthew A. [1 ]
Abbott, Carla J. [2 ,3 ,4 ]
Titchener, Samuel A. [1 ]
Kolic, Maria [3 ]
Kentler, William G. [5 ]
Nayagam, David A. X. [1 ,3 ,6 ]
Baglin, Elizabeth K. [3 ]
Kvansakul, Jessica [1 ]
Barnes, Nick [7 ]
Walker, Janine G. [7 ,8 ]
Karapanos, Lewis [3 ,4 ,9 ]
McGuinness, Myra B. [3 ,4 ]
Ayton, Lauren N. [3 ,4 ]
Luu, Chi D. [3 ,4 ]
Allen, Penelope J. [3 ,4 ,10 ]
机构
[1] Bion Inst, Melbourne, Vic, Australia
[2] Univ Melbourne, Med Dept Bion, Melbourne, Vic, Australia
[3] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia
[4] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia
[5] Univ Melbourne, Dept Biomed Engn, Melbourne, Vic, Australia
[6] Univ Melbourne, St Vincents Hosp, Dept Pathol, Melbourne, Vic, Australia
[7] Australian Natl Univ, Res Sch Engn, Canberra, ACT, Australia
[8] CSIRO, Hlth & Biosecur, Canberra, ACT, Australia
[9] Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Australia
[10] Royal Victorian Eye & Ear Hosp, Vitreoretinal Unit, Melbourne, Australia
来源
OPHTHALMOLOGY SCIENCE | 2025年 / 5卷 / 01期
基金
英国医学研究理事会;
关键词
Suprachoroidal retinal prosthesis; Functional vision; Bionic eye; Retinitis; pigmentosa; QUALITY-OF-LIFE; FUNCTIONAL VISION; BLIND SUBJECTS; VISUAL PERFORMANCE; SYSTEM; PART;
D O I
10.1016/j.xops.2024.100525
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To assess the feasibility of a second-generation (44-channel) suprachoroidal retinal prosthesis for provision of functional vision in recipients with end-stage retinitis pigmentosa (RP) over 2.7 years. Design: Prospective, single-arm, unmasked interventional clinical trial. Participants: Four participants, with advanced RP and bare-light perception vision. Methods: The 44-channel suprachoroidal retinal prosthesis was implanted in the worse-seeing eye. Device stability, functionality, and adverse events were investigated at approximately 12-week intervals up to 140 weeks (2.7 years) postdevice activation. Main Outcome Measures: Serious adverse event (SAE) reporting, visual response outcomes, functional vision outcomes, and quality-of-life outcomes. Results: All 4 participants (aged 39-66 years, 3 males) were successfully implanted in 2018, and there were no device-related SAEs over the duration of the study. A mild postoperative subretinal hemorrhage was detected in 2 recipients, which cleared spontaneously within 2 weeks. OCT confirmed device stability and position under the macula. Improvements in localization abilities were demonstrated for all 4 participants in screen-based, tabletop, and orientation and mobility tasks. In addition, 3 of 4 participants recorded improvements in motion discrimination and 2 of 4 participants recorded substantial improvements in spatial discrimination and identification of tabletop objects. Participants reported their unsupervised use of the device included exploring new environments, detecting people, and safely navigating around obstacles. A positive effect of the implant on participants' daily lives in their local environments was confirmed by an orientation and mobility assessor and participant self-report. Emotional well-being was not impacted by device implantation or usage. Conclusions: The completed clinical study demonstrates that the suprachoroidal prosthesis raises no safety concerns and provides improvements in functional vision, activities of daily living, and observer-rated quality of life. (c) 2024 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
引用
收藏
页数:17
相关论文
共 49 条
  • [31] A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy
    Hurvitz, Noa
    Dinur, Tama
    Revel-Vilk, Shoshana
    Agus, Samuel
    Berg, Marc
    Zimran, Ari
    Ilan, Yaron
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (11)
  • [32] ANNE: A phase II single-arm clinical trial to assess the feasibility and efficacy of neoadjuvant anastrozole in patients with luminal breast cancer and low proliferative index in TNM stages II and III
    Paiva, Carlos
    Oliveira, Izabella
    Guimaraes, Vitor
    Faria, Alinne
    Lacerda, Domicio
    Uema, Anapaula
    Onari, Nilton
    Paiva, Bianca
    Antoniazzi, Augusto
    Oikawa, Karina
    Machado, Maria Fernanda
    Godinho, Matheus
    Souza, Cristiano
    Amirati, Chrissie
    Teixeira, Gustavo
    de Oliveira, Idam, Jr.
    Marques, Marcia
    Maia, Yara
    CANCER RESEARCH, 2024, 84 (09)
  • [33] Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial
    Qiu, Xin
    Lu, Changchang
    Sha, Huizi
    Zhu, Yahui
    Kong, Weiwei
    Tong, Fan
    Wang, Qiaoli
    Meng, Fanyan
    Liu, Baorui
    Du, Juan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [34] Efficacy and safety of second-line therapy by S-1 combined with Sintilimab and Anlotinib in pancreatic cancer patients with liver metastasis: A single-arm, phase II clinical trial.
    Du, Juan
    Qiu, Xin
    Lu, Changchang
    Sha, Huizi
    Zhu, Yahui
    Kong, Weiwei
    Li, Xing
    Qian, Xiaoping
    Liu, Baorui
    CANCER RESEARCH, 2022, 82 (12)
  • [35] Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial
    Liu, Quan
    Xu, Juan-Ying
    Xu, Ye-Hong
    Chen, Meng
    Deng, Li-Chun
    Wu, Jian-Ping
    Zhou, Tong
    Zhang, Li-Qin
    Tan, Jie
    Pu, Xing-Xiang
    Shang, Yu-Long
    Hua, Jun
    Li, Yuan-Qin
    Cai, Wei
    Gu, Yu-Lan
    Peng, Xing-Chen
    Chan, Po-Chung
    Jabbour, Salma K.
    Nam, Hae-Seong
    Hua, Dong
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (05) : 832 - +
  • [36] Nab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial
    Wei, Jing
    Zhang, Pengfei
    Hu, Qiancheng
    Cheng, Xiaolong
    Shen, Chaoyong
    Chen, Zhixin
    Zhuang, Wen
    Yin, Yuan
    Zhang, Bo
    Gou, Hongfeng
    Yang, Kun
    Bi, Feng
    Liu, Ming
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [37] A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.
    Wang, Feng
    Xia, Jin
    Meng, Xiangrui
    Ji, Yinghua
    Yang, Xiuli
    Hong, Yong-Gui
    Wang, Junsheng
    Cui, Donghai
    Luo, Zhiquan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Preliminary results of surufatinib (Suru) plus standard chemotherapy (ChT) as second line (2L) treatment of advanced gastric cancer (aGC): A single-arm, phase 2 clinical trial.
    Han, Ting
    Lin, Xiaolin
    Zhuo, Meng
    Jiao, Feng
    Cui, Jiujie
    Qiu, Xiaoxia
    Xiao, Xiuying
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 353 - 353
  • [39] Apatinib plus etoposide as second-or higher-line treatment in recurrent or metastatic triple-negative breast cancer: A single-arm, open label, prospective, phase II clinical trial.
    Cao, Mengru
    Lu, Hailing
    Yan, Shi
    Pang, Hui
    Sun, Lichun
    Li, Chunhong
    Chen, Xuesong
    Liu, Wei
    Hu, Jing
    Huang, Jian
    Xing, Ying
    Chen, Yingqi
    He, Ting
    Zhao, Danni
    Sun, Yuanyuan
    Zhao, Lin
    Liu, Xiaomeng
    Zhang, Ningzhi
    Cai, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Motivational to Weight Loss version 1 (MWL v.1): Protocol for a feasibility single-arm, openlabel clinical trial of a motivational interviewing, stages and processes of change-based intervention for weight loss in adults
    de Carvalho, Quenia
    Ziani, Paola Rampelotto
    Goularte, Jeferson Ferraz
    Rosa, Adriane R.
    RBONE-REVISTA BRASILEIRA DE OBESIDADE NUTRICAO E EMAGRECIMENTO, 2024, 18 (113): : 355 - 369